Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ADC THERAPEUTICS SA

(ADCT)
  Report
Delayed Nyse  -  01:00 2022-11-25 pm EST
3.590 USD   -2.18%
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
11/14Morgan Stanley Adjusts Price Target on ADC Therapeutics SA to $7 From $11, Maintains Equal-Weight Rating
MT
11/09BofA Securities Downgrades ADC Therapeutics to Neutral From Buy, Adjusts Price Target to $7 From $14
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/18/2022 11/21/2022 11/22/2022 11/23/2022 11/25/2022 Date
3.92(c) 3.77(c) 3.74(c) 3.67(c) 3.59(c) Last
418 699 328 251 327 592 319 241 143 506 Volume
-2.24% -3.83% -0.80% -1.87% -2.18% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 196 M - -
Net income 2022 -159 M - -
Net cash position 2022 309 M - -
P/E ratio 2022 -1,76x
Yield 2022 -
Sales 2023 174 M - -
Net income 2023 -203 M - -
Net cash position 2023 147 M - -
P/E ratio 2023 -1,59x
Yield 2023 -
Capitalization 287 M 287 M -
EV / Sales 2022 -0,11x
EV / Sales 2023 0,80x
Nbr of Employees 312
Free-Float 46,9%
More Financials
Company
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple... 
Sector
Biotechnology & Medical Research
Calendar
12/10 | 04:15pmPresentation
More about the company
Ratings of ADC Therapeutics SA
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about ADC THERAPEUTICS SA
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
11/14Morgan Stanley Adjusts Price Target on ADC Therapeutics SA to $7 From $11, Maintains Eq..
MT
11/09BofA Securities Downgrades ADC Therapeutics to Neutral From Buy, Adjusts Price Target t..
MT
11/09RBC Cuts Price Target on ADC Therapeutics to $20 From $25, Notes Delay in Potential Cam..
MT
11/08Transcript : ADC Therapeutics SA, Q3 2022 Earnings Call, Nov 08, 2022
CI
11/08Earnings Flash (ADCT) ADC THERAPEUTICS SA Posts Q3 Revenue $76.3M
MT
11/08Earnings Flash (ADCT) ADC THERAPEUTICS SA Posts Q3 EPS $0.13
MT
11/08Adc Therapeutics : Purchase Agreement - Form 6-K
PU
11/08ADC Therapeutics SA Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
11/08ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Upd..
BU
11/07ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
BU
11/03ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual M..
BU
11/02IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evalu..
BU
11/02IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evalu..
AQ
11/02IGM Biosciences, Inc. Enters into Clinical Trial Collaboration and Supply Agreement wit..
CI
More news
News in other languages on ADC THERAPEUTICS SA
11/09ADC Therapeutics publie ses résultats financiers du troisième trimestre 2022 et fait le..
11/09ADC Therapeutics meldet Finanzergebnisse für das dritte Quartal 2022 und gibt aktuelle ..
11/08ADC Therapeutics SA annonce ses résultats pour le troisième trimestre et les neuf mois ..
11/07ADC Therapeutics prendra part à la Jefferies London Healthcare Conference
11/07ADC Therapeutics meldet Teilnahme an Jefferies London Healthcare Conference
More news
Analyst Recommendations on ADC THERAPEUTICS SA
More recommendations
ETFs positioned on ADC THERAPEUTICS SAETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Direxion Fallen Knives ETF - USD0.46%-9.78%-NC
ALPS Medical Breakthroughs ETF - USD0.37%-0.21%United_States
IShares Biotechnology ETF - USD0.02%0.06%-NC
BMO MSCI Genomic Innovation Index ETF - CAD0.02%0.00%-NC
More ETFs positioned on ADC THERAPEUTICS SA
Chart ADC THERAPEUTICS SA
Duration : Period :
ADC Therapeutics SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADC THERAPEUTICS SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 3,59 $
Average target price 14,17 $
Spread / Average Target 295%
EPS Revisions
Managers and Directors
Ameet Mallik President, Chief Executive Officer & Director
Jennifer Creel Chief Financial Officer
Ron Squarer Chairman
Patrick van Berkel Chief Scientific Officer
Joseph S. Camardo Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ADC THERAPEUTICS SA-82.23%287
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.44%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930